Ralph Kern, M.D., MHSc

Ralph Kern, M.D., MHSc

Chief Operating Officer and Chief Medical Officer

Ralph Kern MD MHSc is Chief Operating Officer and Chief Medical Officer at BrainStorm Cell Therapeutics.  He completed neurology training at McGill University, practiced neuromuscular neurology at Mount Sinai Hospital in Toronto and was head of the post graduate academic neurology program at the University of Toronto.  He completed further post graduate training in heath administration at the Institute for Health Policy Management and Evaluation at the University of Toronto.  Ralph received his MD degree from Queen’s University, is board certified in neurology and neuromuscular disease, and is a member of the Royal College of Physicians and Surgeons of Canada.

Ralph joined Genzyme in 2006 where he led Genzyme medical activities in Canada and moved to Boston where he led Fabrazyme global commercial activities as general manager in the personalized genetic health business.   Subsequently he joined Novartis in 2011, where he assumed the role of VP and head of the neuroscience medical unit, leading the global launch of Gilenya.  Subsequently Ralph moved to Biogen in 2015 where he assumed the role of SVP and head of the worldwide medical organization- his team launched Zinbryta in MS and Spinraza in SMA and developed the medical and scientific strategy for MS, SMA and Alzheimer’s disease.